Traws Pharma
TRAW
9 hedge funds and large institutions have $3.53M invested in Traws Pharma in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
13% more funds holding
Funds holding: 8 → 9 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
19% less capital invested
Capital invested by funds: $4.36M → $3.53M (-$828K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$165K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$124K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.6K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$515K |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$92K |
| 3 |
VF
Virtu Financial
New York
|
-$41.2K |
| 4 |
Renaissance Technologies
New York
|
-$20.6K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$10.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCP
1
Tyndall Capital Partners
New York
| $1.5M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $842K | -$515K | -50 | -33% |
|
|
6CM
3
683 Capital Management
New York
| $697K | +$165K | +16 | +24% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $236K | +$124K | +12 | +75% |
|
|
5
Renaissance Technologies
New York
| $164K | -$20.6K | -2 | -10% |
|
|
PAM
6
Panagora Asset Management
Boston,
Massachusetts
| $53K | -$10.3K | -1 | -14% |
|
|
VF
7
Virtu Financial
New York
| $19K | -$41.2K | -4 | -67% |
|
|
8
Citadel Advisors
Miami,
Florida
| $17K | +$20.6K | +2 | New |
|
|
9
Macquarie Group
Sydney, NSW 2000,
Australia
| $8K | +$10.3K | +1 | New |
|
10
BlackRock
New York
| $1K | – | – | – |
|
|
HFM
11
Hartford Financial Management
Hartford,
Connecticut
| $1K | – | – | – |
|
|
BC
12
Boxer Capital
San Diego,
California
| – | -$92K | -43 | Closed |
|
13
UBS Group
Zurich,
Switzerland
| – | -$1K | – | – |
|
TRAW Hedge Fund Activity: Q4 2017 in Review
9 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2017, worth a combined $3.53M — down 19% from $4.36M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TRAW positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $165K. The largest seller was Sabby Management, cutting an estimated $515K.
- 9 institutional investors held Traws Pharma (TRAW) as of Q4 2017, up from 8 in Q3 2017.
- Funds reported $3.53M of Traws Pharma stock for Q4 2017, down 19% quarter-over-quarter.
- 2 funds opened new Traws Pharma positions in Q4 2017 and 1 closed out, a net change of +1 holder.
- The largest Traws Pharma buyer in Q4 2017 was 683 Capital Management, an estimated $165K added.
- The largest Traws Pharma seller in Q4 2017 was Sabby Management, an estimated $515K sold.
Based on aggregated 13F filings for Q4 2017.